# Internal Review - Claude Code (Round 1)

**Role:** Reviewer 2 (harsh, skeptical) + Editor (constructive)
**Model:** claude-opus-4-6
**Paper:** paper.pdf
**Timestamp:** 2026-02-27T14:00:00

---

## 1. IDENTIFICATION AND EMPIRICAL DESIGN

The identification strategy is credible. The DWP's IT-infrastructure-based rollout ordering provides plausibly exogenous variation in UC adoption timing. The paper uses three complementary estimators (CS-DiD, TWFE, Sun-Abraham) that handle staggered treatment heterogeneity differently. Pre-trends are flat and pass the joint chi-squared test (p=0.887).

**Concern:** The "never-treated" group (43 LAs) needs stronger justification for why they remained untreated — is this truly due to administrative delays or could it reflect systematic differences? The paper addresses this partially but could be more explicit.

## 2. INFERENCE AND STATISTICAL VALIDITY

Standard errors are clustered at the LA level throughout. Wild cluster bootstrap confirms asymptotic results. Sample sizes are reported and consistent across specifications. The power calculation is transparent about the minimum detectable effect.

## 3. ROBUSTNESS AND ALTERNATIVE EXPLANATIONS

Strong suite of robustness checks: alternative estimators, pilot exclusion, sector placebos, high-formation LA placebo. The survivorship bias discussion is thoughtful and addresses a real limitation.

**Suggestion:** Could add a leave-one-out analysis dropping each treatment cohort to verify stability.

## 4. CONTRIBUTION AND LITERATURE POSITIONING

Clear contribution to welfare-and-work literature. Honest null result framing. Good connection to the "sludge" / program complexity literature.

## 5. RESULTS INTERPRETATION

Results interpretation is appropriately cautious. The paper avoids over-claiming from a null result and provides useful bounds.

## 6. ACTIONABLE REVISION REQUESTS

1. **Must-fix:** None (advisor review issues resolved)
2. **High-value:** Consider a map of the rollout geography
3. **Optional:** Additional robustness with leave-one-cohort-out

## 7. OVERALL ASSESSMENT

- **Strengths:** Clean identification, honest null result, comprehensive robustness
- **Weaknesses:** Measurement limitation (Companies House = surviving firms only), limited power for mechanism tests
- **Publishability:** Ready for external review

DECISION: MINOR REVISION
